<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004440</url>
  </required_header>
  <id_info>
    <org_study_id>199/13438</org_study_id>
    <secondary_id>CWRU-FDR001185</secondary_id>
    <nct_id>NCT00004440</nct_id>
  </id_info>
  <brief_title>Study of Ibuprofen to Preserve Lung Function in Patients With Cystic Fibrosis</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>FDA Office of Orphan Products Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Case Western Reserve University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>FDA Office of Orphan Products Development</source>
  <brief_summary>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      I. Determine the effect of different doses of ibuprofen on neutrophil (polymorphonuclear&#xD;
      leukocyte; PMN) delivery to a mucosal surface (the oral mucosa) in patients with cystic&#xD;
      fibrosis and healthy controls.&#xD;
&#xD;
      II. Determine the duration of effect (and possible rebound effect) of ibuprofen on PMN&#xD;
      delivery to a mucosal surface in these patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PROTOCOL OUTLINE:&#xD;
&#xD;
      This is an open label study. Patients are randomized into 5 arms, each consisting of 10&#xD;
      healthy volunteers and 5 patients with cystic fibrosis, based on the amount of ibuprofen&#xD;
      received during the treatment period.&#xD;
&#xD;
      The study period lasts for at least 15 days and consists of 3 periods: baseline (days 1-3),&#xD;
      treatment (days 3-12), and recovery (days 13-15 or longer). During the treatment period&#xD;
      patients receive ibuprofen orally every 12 hours (except for a control arm that receives no&#xD;
      ibuprofen).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 1996</start_date>
  <completion_date>June 1999</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>75</enrollment>
  <condition>Cystic Fibrosis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ibuprofen</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        PROTOCOL ENTRY CRITERIA:&#xD;
&#xD;
        --Disease Characteristics--&#xD;
&#xD;
        Confirmed diagnosis of cystic fibrosis (CF) based on: Sweat chloride greater than 60 mEq/L&#xD;
        AND Typical pulmonary and/or gastrointestinal manifestation of CF OR Healthy volunteers&#xD;
&#xD;
        --Prior/Concurrent Therapy--&#xD;
&#xD;
        At least 30 days since medications with anti-neutrophil or anti-inflammatory effect (e.g.,&#xD;
        aspirin, nonsteroidal anti-inflammatory drugs [NSAIDs], corticosteroids, macrolide&#xD;
        antibiotics)&#xD;
&#xD;
        --Patient Characteristics--&#xD;
&#xD;
        Age: Patients with cystic fibrosis (CF): 5 and over; Healthy volunteers: 18 and over&#xD;
&#xD;
        Hematopoietic: No significant history of hematologic disease&#xD;
&#xD;
        Hepatic: No significant history of hepatic disease&#xD;
&#xD;
        Renal: No significant history of renal disease&#xD;
&#xD;
        Cardiovascular: No significant history of cardiovascular disease&#xD;
&#xD;
        Pulmonary: See Disease Characteristics&#xD;
&#xD;
        Neurologic: No significant history of neurologic disease&#xD;
&#xD;
        Other: Not pregnant; No significant history of peptic ulcer disease; Patients with CF free&#xD;
        of any acute illness within 14 days; No prior hypersensitivity to any NSAID&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael W Konstan</last_name>
    <role>Study Chair</role>
    <affiliation>Case Western Reserve University</affiliation>
  </overall_official>
  <verification_date>April 2000</verification_date>
  <study_first_submitted>October 18, 1999</study_first_submitted>
  <study_first_submitted_qc>October 18, 1999</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 1999</study_first_posted>
  <last_update_submitted>March 24, 2015</last_update_submitted>
  <last_update_submitted_qc>March 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 25, 2015</last_update_posted>
  <keyword>cardiovascular and respiratory diseases</keyword>
  <keyword>cystic fibrosis</keyword>
  <keyword>genetic diseases and dysmorphic syndromes</keyword>
  <keyword>rare disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibuprofen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

